about
Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogsLigand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptorChanges in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormoneAntagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissuesLipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaTherapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxelPotentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonistPowerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.An audit of using the H Pipelle for endometrial sampling at outpatient hysteroscopy and literature review comparison with the Pipelle de Cornier.Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
P50
Q24292089-1D3C241D-AE0C-46C0-B6EC-DD72F9773DAFQ24309176-8533672B-9034-4B5F-B118-2016E515769BQ33894753-06A3C947-880A-44A1-9AB2-87DC916EF79EQ33906715-464E8AC6-8528-4400-8A2C-B90290A05F81Q33974134-A1C965B2-F2BD-4421-82C6-347EAB728FF1Q34139838-FC38697E-BCCB-4CCE-B699-E9D708F697C7Q34161110-164373AB-7B7C-4998-B716-4413A221426FQ34574865-08D34B57-814D-4DED-AAEC-0F1C81312BE5Q34621536-1ECC9F50-DF46-4A31-86AD-8251A387C468Q34772221-6EBCF5F4-BAFD-43EA-8CB7-E6E44098D1EFQ35080727-657B6AA1-629A-4377-A479-902FE8D7D68EQ35629436-5E63E2EB-B0D5-40F0-8E14-25228121EDFBQ36161621-BB27F484-DA62-43F9-8A43-E9D6ECF5D800Q36236479-6163DCA5-1B77-4903-BDE4-05686F205BEBQ36276948-FD187702-09E4-421F-B6CC-D15D5BA52C87Q36617058-7A0FD752-136D-405E-A2B7-B8D59728F702Q37093547-8030A398-17C6-4577-9E8F-4998B98F4486Q37381602-C2AFF70F-863A-4333-8141-D0AD44E6D3F7Q37589369-42F81A08-265C-4FDA-AD24-DB9E2A5AEE0AQ38033883-96CEE6F2-84EC-4F0D-AB2D-C422AB53719EQ38331590-B8108BEC-AAC1-48C4-9FFB-4B448F62C4C8Q39499342-CE0730A4-6FED-40DA-A165-9B353E28FA3EQ39739294-14B64B27-DB88-4790-80EA-0490CEF9727DQ39799354-706237CF-04ED-4BEE-A5FA-5456053D8B52Q39838321-4F1DD3F6-783A-4E90-9A10-39A84CFF2DA1Q39843556-0DC00984-C63D-48C7-B1AA-A8396DE39490Q39946886-30609274-9715-4F26-964F-111659E081C8Q39985777-4556BB3C-9572-4435-A57D-2D4F452BA2EAQ40108372-82DC7F27-1DD0-4E31-B857-17C9A13D0520Q40259032-F3F60908-F55C-421D-B7A1-19C89A7689FFQ40281779-C33175AD-AAD8-4C9B-90FA-06FCCC6CC87BQ40364429-FC6CEC9F-2674-46DE-B6EF-94317BD79252Q40369418-E3BCF584-CA29-4FEC-8113-21AC2B2122DEQ40371237-EECC563B-C85A-40A9-B3A3-5B6CC477C352Q40390236-EDEC80AB-46EB-4805-9AB1-9D1D265A841BQ40392060-DE5968BD-60E0-4469-9C4A-78F4E3AE8AE6Q40392702-A2D83B96-1185-4834-9B8F-BE7EC9E12937Q40394065-3E0D6D8D-9AD7-4511-BCBB-B0359BFF89F1Q40402230-858DFA5E-EA75-41F2-96C9-C5383A381C69Q40412527-C4DE86C5-1949-4F78-978A-BF7EFBBE93A2
P50
name
Gabor Halmos
@en
type
label
Gabor Halmos
@en
prefLabel
Gabor Halmos
@en